Somewhat Positive Press Coverage Somewhat Unlikely to Impact Zosano Pharma Corporation (ZSAN) Stock Price

News stories about Zosano Pharma Corporation (NASDAQ:ZSAN) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zosano Pharma Corporation earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.8337625223523 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

• Needle Action Activity Spotted in Zosano Pharma Corp (ZSAN) – Financial News Review (finnewsreview.com)
• Zosano Pharma Corporation (ZSAN) Stock Price trades -40.96% off from 200- SMA: Zosano Pharma Corporation (ZSAN) – Voice Of Analysts (analystsbuzz.com)
• Zosano Pharma Corporation (ZSAN) – Momentum Stock in Focus – Wall Street Morning (wallstreetmorning.com)
• Changes in Signals Identified: Zosano Pharma Corporation (ZSAN), Interpace Diagnostics Group, Inc. (IDXG) – AllStockNews (allstocknews.com)
• Can Zosano Pharma Corp (NASDAQ:ZSAN) Stock Turn Around? – Stock News Union (blog) (stocknewsunion.com)

Zosano Pharma Corporation (NASDAQ ZSAN) traded down 2.5595% during mid-day trading on Friday, hitting $0.8185. 359,305 shares of the company traded hands. The stock’s market capitalization is $32.11 million. The company’s 50-day moving average is $1.19 and its 200-day moving average is $1.57. Zosano Pharma Corporation has a one year low of $0.45 and a one year high of $3.54.

Zosano Pharma Corporation (NASDAQ:ZSAN) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. During the same period in the prior year, the company posted ($0.54) earnings per share. Analysts predict that Zosano Pharma Corporation will post ($0.79) EPS for the current year.

Separately, ValuEngine raised shares of Zosano Pharma Corporation from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 6th.

TRADEMARK VIOLATION WARNING: This report was originally posted by [[site]] and is the sole property of of [[site]]. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at [[permalink]].

In other news, CFO Georgia Erbez purchased 68,000 shares of Zosano Pharma Corporation stock in a transaction dated Thursday, May 25th. The shares were bought at an average cost of $1.32 per share, for a total transaction of $89,760.00. Following the completion of the acquisition, the chief financial officer now owns 115,750 shares in the company, valued at approximately $152,790. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO John Peter Walker purchased 73,716 shares of Zosano Pharma Corporation stock in a transaction dated Thursday, May 25th. The shares were purchased at an average price of $1.36 per share, for a total transaction of $100,253.76. Following the completion of the acquisition, the chief executive officer now owns 169,344 shares of the company’s stock, valued at approximately $230,307.84. The disclosure for this purchase can be found here. Insiders own 2.95% of the company’s stock.

Zosano Pharma Corporation Company Profile

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.